Previous studies have placed emphasis on evaluating known AD biomarkers, such as Aβ or tau isoforms in various peripheral body fluids, such as saliva (Sabbagh et al., 2018) or serum (Li and Mielke, 2019). This evidence concerns the gene MAPT and Alzheimer disease.